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In the title compound, C16H14N2OS, the quinazoline ring
system is essentially planar, with a maximum deviation of
0.029 (3) A ˚ . The dihedral angle between the quinazoline and
benzene rings is 88.4 (2) . In the crystal, adjacent molecules
are connected via pairs of N—H   S and C—H   O hydrogen





respectively, resulting in a supramolecular chain along the a
axis.
Related literature
For details and applications of quinazoline compounds, see:
Roth & Fenner (2000); Jantova et al. (2004); Harris & Thor-
arensen (2004); Andries et al. (2005); Al-Rashood et al. (2006);
Ghorab et al. (2007); Ra ´dl et al. (2000); Klepser & Klepser
(1997); Al-Omar et al. (2004); Al-Omary et al. (2010). For
hydrogen-bond motifs, see: Bernstein et al. (1995). For bond-






a = 24.2438 (18) A ˚
b = 5.1618 (5) A ˚
c = 24.4265 (17) A ˚
  = 111.532 (6) 
V = 2843.4 (4) A ˚ 3
Z =8
Cu K  radiation
  = 1.99 mm
 1
T = 296 K
0.83   0.12   0.06 mm
Data collection




Tmin = 0.289, Tmax = 0.890
9528 measured reﬂections
2592 independent reﬂections












 max = 0.24 e A ˚  3
 min =  0.21 e A ˚  3
Table 1
Hydrogen-bond geometry (A ˚ ,  ).
D—H   AD —H H   AD    AD —H   A
N1—H1A   S1
i 0.86 2.50 3.335 (3) 165
C4—H4A   O1
ii 0.93 2.41 3.295 (4) 159
Symmetry codes: (i)  x þ 1
2; y þ 1
2; z; (ii)  x; y þ 2; z.
Data collection: APEX2 (Bruker, 2009); cell reﬁnement: SAINT
(Bruker, 2009); data reduction: SAINT; program(s) used to solve
structure: SHELXTL (Sheldrick, 2008); program(s) used to reﬁne
structure: SHELXTL; molecular graphics: SHELXTL; software used
to prepare material for publication: SHELXTL and PLATON (Spek,
2009).
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3-Benzyl-6-methyl-2-sulfanylidene-2,3-dihydroquinazolin-4(1H)-one
Rashad Al-Salahi, Mohamed Al-Omar, Hussein El-Subbagh, Madhukar Hemamalini and Hoong-
Kun Fun
Comment 
Quinazoline moiety is present in many classes of biologically-active compounds. A number of them have been clinically 
used as antifungal, antibacterial and antiprotozoic drugs (Roth & Fenner, 2000; Jantova et al., 2004; Harris & 
Thorarensen, 2004), as well as antituberculotic agents (Andries et al., 2005). Furthermore, they have drawn much 
attention due to their broad range of pharmacological properties which include antitumor (Al-Rashood et al., 2006), 
anticancer (Ghorab et al., 2007) and analgesic (Rádl et al., 2000) properties. Certain quinazoline analogs also showed 
remarkable activity against the opportunistic infections of Pneumocystis carinii and Toxoplasma gondii. Those 
microorganisms proved to be the priniciple cause of death in patients with immunocompromised diseases such as 
acquired immune deficiency syndrome (Klepser & Klepser, 1997). This work is a continuation of this program with the 
aim of obtaining an interesting series of quinazolines that contain the thioxo functional group which was identified as a 
possible pharmacophore of the antimicrobial activity (Al-Omar et al., 2004; Al-Omary et al., 2010).
The molecular structure of the title compound is shown in Fig. 1. The quinazoline (N1,N2/C1–C8) ring is essentially 
planar, with a maximum deviation of 0.029 (3) Å for atom C2. The dihedral angle between the quinazoline (N1,N2/C1–
C8) and the benzene (C10–C15) rings is 88.4 (2)°. The bond lengths (Allen et al., 1987) and angles are within normal 
ranges. In the crystal, (Fig. 2), the adjacent molecules are connected via a pair of N—H···S and C—H···O (Table 1) 
hydrogen bonds, generating R2
2(8) and R2
2(10) graph-set motifs (Bernstein et al., 1995), respectively, resulting in a 
supramolecular [100] chain.
Experimental 
A mixture of benzyl isothiocyanate (10 mmol) and 2-amino-5-methyl benzoic acid (10 mmol) in ethanol (30 ml) was 
heated under reflux in the presence of triethylamine (5 mmol) for 2 h. After cooling, the mixture was poured into 
ice/water. The resulting solid was filtered, washed with water and dried. Recrystallization from ethanol gave 3-
benzyl-2,3-dihydro-6-methyl-2-thioxo-quinazoline-4(1H)-one as colorless crystals.
Refinement 
All H atoms were positioned geometrically (N—H = 0.86 Å and C—H = 0.93–0.97 Å) and were refined using a riding 
model, with Uiso(H) = 1.2 or 1.5Ueq(C). A rotating group model was applied to the methyl groups.
Computing details 
Data collection: APEX2 (Bruker, 2009); cell refinement: SAINT (Bruker, 2009); data reduction: SAINT (Bruker, 2009); 
program(s) used to solve structure: SHELXTL (Sheldrick, 2008); program(s) used to refine structure: SHELXTL 
(Sheldrick, 2008); molecular graphics: SHELXTL (Sheldrick, 2008); software used to prepare material for publication: 
SHELXTL (Sheldrick, 2008) and PLATON (Spek, 2009).supplementary materials
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Figure 1
The molecular structure of the title compound, showing 30% probability displacement ellipsoids. 
Figure 2






Hall symbol: -C 2yc
a = 24.2438 (18) Å
b = 5.1618 (5) Å
c = 24.4265 (17) Å
β = 111.532 (6)°
V = 2843.4 (4) Å3
Z = 8
F(000) = 1184
Dx = 1.319 Mg m−3
Cu Kα radiation, λ = 1.54178 Å
Cell parameters from 339 reflections
θ = 3.9–53.5°
µ = 1.99 mm−1
T = 296 K
Needle, colourless
0.83 × 0.12 × 0.06 mmsupplementary materials
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Data collection 
Bruker SMART APEXII CCD 
diffractometer
Radiation source: fine-focus sealed tube
Graphite monochromator
φ and ω scans
Absorption correction: multi-scan 
(SADABS; Bruker, 2009)
Tmin = 0.289, Tmax = 0.890
9528 measured reflections
2592 independent reflections
1421 reflections with I > 2σ(I)
Rint = 0.104













Primary atom site location: structure-invariant 
direct methods
Secondary atom site location: difference Fourier 
map




2) + (0.0875P)2] 




Δρmax = 0.24 e Å−3
Δρmin = −0.21 e Å−3
Special details 
Geometry. All s.u.'s (except the s.u. in the dihedral angle between two l.s. planes) are estimated using the full covariance 
matrix. The cell s.u.'s are taken into account individually in the estimation of s.u.'s in distances, angles and torsion angles; 
correlations between s.u.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell s.u.'s is used for estimating s.u.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, 
conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2σ(F2) is 
used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based 
on F2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
xy z U iso*/Ueq
S1 0.22029 (4) 0.1447 (2) 0.07055 (4) 0.0718 (3)
N1 0.17921 (10) 0.4985 (6) −0.01167 (11) 0.0630 (7)
H1A 0.2097 0.4590 −0.0199 0.076*
N2 0.12318 (10) 0.4401 (5) 0.04598 (11) 0.0574 (7)
O1 0.04534 (10) 0.7057 (5) 0.03541 (11) 0.0747 (7)
C1 0.17206 (13) 0.3706 (7) 0.03308 (14) 0.0594 (8)
C2 0.08423 (13) 0.6424 (7) 0.01808 (14) 0.0600 (8)
C3 0.09395 (12) 0.7664 (7) −0.03127 (13) 0.0585 (8)
C4 0.05611 (13) 0.9575 (7) −0.06444 (14) 0.0630 (9)
H4A 0.0243 1.0100 −0.0544 0.076*
C5 0.06438 (15) 1.0717 (7) −0.11196 (15) 0.0691 (9)
C6 0.11382 (16) 0.9891 (8) −0.12434 (16) 0.0763 (10)
H6A 0.1206 1.0638 −0.1559 0.092*
C7 0.15210 (15) 0.8048 (7) −0.09221 (15) 0.0715 (10)
H7A 0.1848 0.7578 −0.1013 0.086*
C8 0.14201 (13) 0.6879 (7) −0.04573 (14) 0.0578 (8)
C9 0.10920 (14) 0.2997 (7) 0.09172 (15) 0.0657 (9)supplementary materials
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H9A 0.1263 0.1276 0.0958 0.079*
H9B 0.0665 0.2799 0.0788 0.079*
C10 0.13111 (14) 0.4281 (7) 0.15093 (14) 0.0641 (9)
C11 0.1103 (2) 0.3376 (10) 0.1930 (2) 0.0988 (15)
H11A 0.0831 0.2022 0.1840 0.119*
C12 0.1298 (3) 0.4483 (15) 0.2483 (2) 0.131 (2)
H12A 0.1144 0.3902 0.2758 0.157*
C13 0.1710 (3) 0.6401 (16) 0.2634 (2) 0.133 (2)
H13A 0.1854 0.7057 0.3015 0.160*
C14 0.1912 (2) 0.7364 (11) 0.2216 (2) 0.1082 (15)
H14A 0.2179 0.8737 0.2306 0.130*
C15 0.17129 (17) 0.6268 (8) 0.16567 (16) 0.0783 (11)
H15A 0.1856 0.6898 0.1377 0.094*
C16 0.02217 (18) 1.2711 (9) −0.14931 (18) 0.0893 (12)
H16B −0.0064 1.3143 −0.1321 0.134*
H16A 0.0021 1.2027 −0.1881 0.134*
H16C 0.0438 1.4238 −0.1516 0.134*
Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
S1 0.0640 (5) 0.0875 (7) 0.0707 (6) 0.0172 (4) 0.0327 (5) 0.0084 (5)
N1 0.0558 (14) 0.083 (2) 0.0576 (17) 0.0153 (13) 0.0295 (14) 0.0029 (15)
N2 0.0510 (13) 0.0688 (18) 0.0577 (16) 0.0036 (11) 0.0264 (13) −0.0049 (13)
O1 0.0601 (12) 0.0924 (19) 0.0855 (17) 0.0135 (11) 0.0430 (13) −0.0007 (13)
C1 0.0500 (16) 0.076 (2) 0.0554 (19) 0.0024 (14) 0.0231 (16) −0.0121 (17)
C2 0.0498 (16) 0.073 (2) 0.059 (2) 0.0022 (14) 0.0228 (16) −0.0124 (17)
C3 0.0472 (16) 0.076 (2) 0.051 (2) −0.0010 (14) 0.0169 (16) −0.0104 (17)
C4 0.0543 (17) 0.070 (2) 0.066 (2) 0.0069 (15) 0.0225 (17) −0.0068 (18)
C5 0.065 (2) 0.074 (2) 0.066 (2) 0.0057 (16) 0.0211 (18) −0.0006 (19)
C6 0.077 (2) 0.086 (3) 0.072 (2) 0.0089 (18) 0.035 (2) 0.008 (2)
C7 0.068 (2) 0.090 (3) 0.068 (2) 0.0134 (17) 0.0375 (19) 0.009 (2)
C8 0.0472 (16) 0.073 (2) 0.0540 (19) 0.0062 (13) 0.0194 (15) −0.0060 (16)
C9 0.0629 (19) 0.065 (2) 0.080 (2) −0.0013 (14) 0.0393 (19) −0.0001 (18)
C10 0.0643 (18) 0.074 (2) 0.063 (2) 0.0196 (16) 0.0343 (18) 0.0090 (18)
C11 0.115 (3) 0.114 (4) 0.090 (3) 0.020 (3) 0.065 (3) 0.028 (3)
C12 0.150 (6) 0.185 (7) 0.080 (4) 0.064 (5) 0.069 (4) 0.043 (4)
C13 0.131 (5) 0.196 (7) 0.068 (3) 0.061 (4) 0.031 (4) −0.018 (4)
C14 0.108 (4) 0.117 (4) 0.092 (3) 0.010 (3) 0.027 (3) −0.030 (3)
C15 0.082 (2) 0.089 (3) 0.066 (3) 0.002 (2) 0.029 (2) −0.011 (2)
C16 0.082 (3) 0.091 (3) 0.092 (3) 0.014 (2) 0.028 (2) 0.012 (2)
Geometric parameters (Å, º) 
S1—C1 1.667 (3) C7—H7A 0.9300
N1—C1 1.342 (4) C9—C10 1.500 (5)
N1—C8 1.382 (4) C9—H9A 0.9700
N1—H1A 0.8600 C9—H9B 0.9700
N2—C1 1.381 (3) C10—C15 1.369 (5)
N2—C2 1.405 (4) C10—C11 1.381 (5)supplementary materials
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N2—C9 1.472 (4) C11—C12 1.382 (7)
O1—C2 1.212 (3) C11—H11A 0.9300
C2—C3 1.458 (4) C12—C13 1.357 (9)
C3—C4 1.388 (5) C12—H12A 0.9300
C3—C8 1.396 (4) C13—C14 1.377 (8)
C4—C5 1.381 (5) C13—H13A 0.9300
C4—H4A 0.9300 C14—C15 1.390 (6)
C5—C6 1.406 (5) C14—H14A 0.9300
C5—C16 1.501 (5) C15—H15A 0.9300
C6—C7 1.359 (5) C16—H16B 0.9600
C6—H6A 0.9300 C16—H16A 0.9600
C7—C8 1.385 (4) C16—H16C 0.9600
C1—N1—C8 126.0 (2) N2—C9—C10 114.6 (3)
C1—N1—H1A 117.0 N2—C9—H9A 108.6
C8—N1—H1A 117.0 C10—C9—H9A 108.6
C1—N2—C2 124.2 (3) N2—C9—H9B 108.6
C1—N2—C9 120.1 (3) C10—C9—H9B 108.6
C2—N2—C9 115.7 (2) H9A—C9—H9B 107.6
N1—C1—N2 115.9 (3) C15—C10—C11 118.5 (4)
N1—C1—S1 121.1 (2) C15—C10—C9 123.4 (3)
N2—C1—S1 123.0 (2) C11—C10—C9 118.1 (4)
O1—C2—N2 120.1 (3) C10—C11—C12 120.0 (5)
O1—C2—C3 123.6 (3) C10—C11—H11A 120.0
N2—C2—C3 116.3 (2) C12—C11—H11A 120.0
C4—C3—C8 119.5 (3) C13—C12—C11 121.3 (5)
C4—C3—C2 121.5 (3) C13—C12—H12A 119.3
C8—C3—C2 119.0 (3) C11—C12—H12A 119.3
C5—C4—C3 121.7 (3) C12—C13—C14 119.3 (5)
C5—C4—H4A 119.1 C12—C13—H13A 120.4
C3—C4—H4A 119.1 C14—C13—H13A 120.4
C4—C5—C6 116.7 (3) C13—C14—C15 119.5 (6)
C4—C5—C16 121.8 (3) C13—C14—H14A 120.3
C6—C5—C16 121.5 (3) C15—C14—H14A 120.3
C7—C6—C5 122.9 (3) C10—C15—C14 121.3 (4)
C7—C6—H6A 118.5 C10—C15—H15A 119.3
C5—C6—H6A 118.5 C14—C15—H15A 119.3
C6—C7—C8 119.3 (3) C5—C16—H16B 109.5
C6—C7—H7A 120.3 C5—C16—H16A 109.5
C8—C7—H7A 120.3 H16B—C16—H16A 109.5
N1—C8—C7 122.0 (3) C5—C16—H16C 109.5
N1—C8—C3 118.3 (3) H16B—C16—H16C 109.5
C7—C8—C3 119.7 (3) H16A—C16—H16C 109.5
C8—N1—C1—N2 −0.9 (5) C1—N1—C8—C7 −178.2 (3)
C8—N1—C1—S1 179.7 (3) C1—N1—C8—C3 3.6 (5)
C2—N2—C1—N1 −4.2 (5) C6—C7—C8—N1 179.7 (4)
C9—N2—C1—N1 176.0 (3) C6—C7—C8—C3 −2.1 (6)
C2—N2—C1—S1 175.1 (2) C4—C3—C8—N1 179.5 (3)supplementary materials
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C9—N2—C1—S1 −4.6 (4) C2—C3—C8—N1 −1.3 (5)
C1—N2—C2—O1 −173.6 (3) C4—C3—C8—C7 1.3 (5)
C9—N2—C2—O1 6.1 (5) C2—C3—C8—C7 −179.6 (3)
C1—N2—C2—C3 6.2 (5) C1—N2—C9—C10 97.0 (3)
C9—N2—C2—C3 −174.1 (3) C2—N2—C9—C10 −82.7 (3)
O1—C2—C3—C4 −4.2 (5) N2—C9—C10—C15 −13.4 (5)
N2—C2—C3—C4 176.0 (3) N2—C9—C10—C11 167.7 (3)
O1—C2—C3—C8 176.6 (3) C15—C10—C11—C12 0.3 (6)
N2—C2—C3—C8 −3.1 (5) C9—C10—C11—C12 179.3 (4)
C8—C3—C4—C5 0.5 (5) C10—C11—C12—C13 −2.3 (8)
C2—C3—C4—C5 −178.6 (3) C11—C12—C13—C14 3.8 (10)
C3—C4—C5—C6 −1.4 (5) C12—C13—C14—C15 −3.2 (8)
C3—C4—C5—C16 177.6 (3) C11—C10—C15—C14 0.2 (6)
C4—C5—C6—C7 0.5 (6) C9—C10—C15—C14 −178.7 (4)
C16—C5—C6—C7 −178.5 (4) C13—C14—C15—C10 1.3 (7)
C5—C6—C7—C8 1.3 (6)
Hydrogen-bond geometry (Å, º) 
D—H···AD —H H···AD ···AD —H···A
N1—H1A···S1i 0.86 2.50 3.335 (3) 165
C4—H4A···O1ii 0.93 2.41 3.295 (4) 159
Symmetry codes: (i) −x+1/2, −y+1/2, −z; (ii) −x, −y+2, −z.